Skip to Main

March 31, 2022

Congresswoman Bourdeaux Applauds Bipartisan Passage Of The Affordable Insulin Now Act

WASHINGTON, DC — Today, Congresswoman Carolyn Bourdeaux (GA-07) applauded the House for passing legislation to cap the out-of-pocket cost for one month’s supply of insulin at $35 or less. Rep. Bourdeaux joined Reps. Angie Craig (MN-2), Daniel T. Kildee (MI-5), Nikema Williams (GA-5), Lucy McBath (GA-6) in introducing H.R. 6833, the Affordable Insulin Now Act, which helps ensure that this life-saving medication is affordable for millions of Americans with diabetes who take insulin and their families.

“At the end of his life, my father struggled with a serious medical condition. His medical care costs drove my parents to drain their savings to keep paying for critical medication, including the insulin my father depended on,” said Congresswoman Carolyn Bourdeaux. “This problem is far from unique. Georgia has one of the highest diabetes rates in the country, and this measure would provide my constituents with meaningful relief. Countless Americans are in the exact same situation my father faced. This legislation ensures no one will have to choose between buying insulin or putting food on their table.”

Rep. Bourdeaux has a long history of fighting for improved health care. She supported a similar provision to cap insulin prices and lower prescription drug costs, address rising care costs, and strengthen Medicare in the Build Back Better Act and is leading the charge to close the Medicaid coverage gap in states like Georgia.

H.R. 6833: The Affordable Insulin Now Act caps out-of-pocket costs for insulin at no more than $35 per month in Medicare Part D and commercial health insurance. Modeled after similar provisions in the Build Back Better Act, this bill ensures vital and affordable access to life-saving medication for the more than 37 million people in the United States who have diabetes, including one-third of Medicare beneficiaries and the over 7 million Americans who rely on insulin to maintain their health and well-being.

Insulin is too expensive for millions of Americans.

  • 1 in 4 Americans who rely on insulin have cut back or skipped doses due to costs.
  • 34 percent of families with children dependent on insulin have been impacted by rising
    insulin costs, including adverse health effects and increased stress and anxiety.
  • 26 percent of Americans with diabetes ration their insulin at least once a year – putting
    themselves at grave health risk because of cost. In 2018, more than a dozen people died while rationing their insulin due to the high cost.

Insulin prices in the United States are much higher than other countries and continue to increase.

  • Americans pay more than 10 times the price of insulin compared to other similar high- income countries.
  • From 2014 to 2019, the average retail price of insulin rose by 54 percent.
  • Among those with private coverage, 1 in 5 people who take insulin have out-of-pocket
    costs of more than $35 per month. High cost-sharing is especially common in the
    individual and small group markets.
  • In a recent study, insulin out-of-pocket costs among all insulin users averaged $64 in
    2017, almost double what the out-of-pocket costs would be with H.R. 6833.

The Affordable Insulin Now Act requires Medicare Part D plans and commercial health
insurance plans to cover insulin and cap cost-sharing at no more than $35 per month.

  • Beginning in 2023, the bill requires private health plans to cover at least one of each type and dosage form of insulin and caps cost-sharing for a 30-day supply at the lesser of $35 or 25 percent of a plan’s negotiated price. The bill also requires all Medicare prescription drug plans to cap cost-sharing for insulin at no more than $35.
    o Among individuals with private insurance, half would save at least $19 per month and a quarter would save at least $42 per month. Individuals who buy their own insurance will experience the most savings.
  • This bill is paid for by delaying the implementation for one year of the Rebate Rule that was published by the Office of the Inspector General of the Department of Health and Human Services on November 30, 2020.

In addition to Rep. Carolyn Bourdeaux, H.R. 6833: The Affordable Insulin Now Act is supported by Rep. Angie Craig (MN-2), Rep. Daniel T. Kildee (MI-5), Rep. Nikema Williams (GA-5), Rep. Lucy McBath (GA-6), Rep. Joseph D. Morelle (NY-25), Rep. Kathy E. Manning (NC-6), Rep. Jahana Hayes (CT-5), Rep. Alma S. Adams (NC-12), Rep. Nanette Diaz Barragan (CA-44), Del. Eleanor Holmes Norton (DC-At Large), Rep. Carolyn B. Maloney (NY-12), Rep. Scott H. Peters (CA-52), Rep. Dina Titus (NV-1), Rep. Joaquin Castro (TX-20), Rep. Nikema Williams (GA-5), Rep. Marcy Kaptur (OH-9), Rep. Mikie Sherrill (NJ-11), Rep. Josh Gottheimer (NJ-5), Rep. Elissa Slotkin (MI-8), Rep. Gerald E. Connolly (VA-11), Rep. Debbie Dingell (MI-12), Rep. Steven Horsford (NV-4), Rep. Lizzie Fletcher (TX-7), Rep. Grace Meng (NY-6), Rep. Bonnie Watson Coleman (NJ-12), Rep. Kim Schrier (WA-8), Rep. Troy Carter (LA-2), Rep. John B. Larson (CT-1), Rep. Dwight Evans (PA-3), Rep. Abigail Davis Spanberger (VA-7), and Rep. Hakeem S. Jeffries (NY-8).


Rep. Carolyn Bourdeaux lives with her family in Suwanee, Georgia, and represents Georgia’s 7th Congressional District in the 117th Congress. Carolyn is a strong advocate for affordable health care, and economic recovery that puts workers and small businesses first, and investing in her district’s world-class public education system and transportation infrastructure. 

Georgia’s fast-changing 7th Congressional District includes portions of the northeast Atlanta metropolitan area, including portions of Forsyth and Gwinnett counties and cities Peachtree Corners, Berkeley Lake, Sugar Hill, Norcross, Cumming, Lawrenceville, Duluth, Snellville, Lilburn, Suwanee, Grayson, and Buford.